With global orphan drug sales rising almost 10% a year from 2005 to 2011, twice as fast as the market as a whole, the current austerity conscious governments are applying the same pricing scrutiny to orphan drugs. But what are the HTA considerations for orphan drugs and future pricing and cost containment to establish and maintain a level that’s going to be sustainable? Download ebook here. (Source: totalbiopharma, 8/12/13).
You are here: / Top HTA Considerations for Orphan Drugs